Literature DB >> 17636407

p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.

Peixin Dong1, Mitsuhiro Tada, Jun-Ichi Hamada, Akihiro Nakamura, Tetsuya Moriuchi, Noriaki Sakuragi.   

Abstract

Dominant negative (DN) mutations of tumor suppressor p53 (TP53) are clinically associated with cancer progression and metastasis of endometrial malignancy. To investigate the DN effect on tumor migration and invasion, we generated cells that stably co-expressed wild-type (wt) and R273H DN mutant TP53 (273H cells), and wt and R213Q recessive mutant TP53 (213Q cells), by transfection in endometrial cancer cells HHUA that expressed wt p53. R273H, but not R213Q, repressed wt p53-stimulated transcription of p21, Bax, and MDM2. 273H cells also showed markedly increased in vitro invasion and migration potentials, and displayed reduced Maspin, PAI-1, and KAI1 mRNA expressions as compared with 213Q and wt cells. The induction of wt p53 function by use of Adriamycin resulted in the inhibition of the invasion/migration capacity in association with the up-regulation of p53 target genes to a far greater degree in 213Q and wt cells than in 273H cells. R273H expression in p53-null cancer cell SK-OV-3 and Saos-2 did not significantly affect cell invasion and migration activities. Taken together, these results suggest that transdominance of R273H mutant over wt p53 rather than a gain-of-function promotes tumor metastasis by increasing invasion and migration in HHUA cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636407     DOI: 10.1007/s10585-007-9084-8

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  43 in total

1.  Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast.

Authors:  Jana Smardová; Sárka Pavlová; Hana Koukalová
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

2.  p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities.

Authors:  Fukun Guo; Yuan Gao; Lei Wang; Yi Zheng
Journal:  J Biol Chem       Date:  2003-02-10       Impact factor: 5.157

3.  Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.

Authors:  C W Miller; A Chumakov; J Said; D L Chen; A Aslo; H P Koeffler
Journal:  Oncogene       Date:  1993-07       Impact factor: 9.867

4.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

5.  Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect.

Authors:  H Fujita; F Okada; J Hamada ; M Hosokawa; T Moriuchi; R C Koya; N Kuzumaki
Journal:  Int J Cancer       Date:  2001-09       Impact factor: 7.396

6.  Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.

Authors:  Wenge Wang; Rishu Takimoto; Farzan Rastinejad; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

7.  Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.

Authors:  M Marutani; H Tonoki; M Tada; M Takahashi; H Kashiwazaki; Y Hida; J Hamada; M Asaka; T Moriuchi
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

8.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

9.  Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells.

Authors:  Valerie A Odero-Marah; Zhila Khalkhali-Ellis; Jirapat Chunthapong; Sumaira Amir; Richard E B Seftor; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

10.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more
  25 in total

1.  Myosin VI is differentially regulated by DNA damage in p53- and cell type-dependent manners.

Authors:  Seong Jun Cho; Xinbin Chen
Journal:  J Biol Chem       Date:  2010-06-23       Impact factor: 5.157

2.  Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Authors:  Paola Monti; Chiara Perfumo; Alessandra Bisio; Yari Ciribilli; Paola Menichini; Debora Russo; David M Umbach; Michael A Resnick; Alberto Inga; Gilberto Fronza
Journal:  Mol Cancer Res       Date:  2011-02-22       Impact factor: 5.852

3.  Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β).

Authors:  Shu Lin; Lan Yu; Junhua Yang; Zhao Liu; Bijal Karia; Alexander J R Bishop; James Jackson; Guillermina Lozano; John A Copland; Xiaoxin Mu; Beicheng Sun; Lu-Zhe Sun
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

Review 4.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

5.  Ultraslow oligomerization equilibria of p53 and its implications.

Authors:  Eviatar Natan; Daniel Hirschberg; Nina Morgner; Carol V Robinson; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

6.  Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.

Authors:  Pradeep Natarajan; Nina B Gold; Alexander G Bick; Heather McLaughlin; Peter Kraft; Heidi L Rehm; Gina M Peloso; James G Wilson; Adolfo Correa; Jonathan G Seidman; Christine E Seidman; Sekar Kathiresan; Robert C Green
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

Review 7.  The tumor suppressor p53: from structures to drug discovery.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02-10       Impact factor: 10.005

8.  Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.

Authors:  Damian J Junk; Lukas Vrba; George S Watts; Marc M Oshiro; Jesse D Martinez; Bernard W Futscher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

9.  p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells.

Authors:  Shui Ping Tu; Alfred L Chi; Walden Ai; Shigeo Takaishi; Zina Dubeykovskaya; Michael Quante; James G Fox; Timothy C Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-06-18       Impact factor: 4.052

10.  Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.

Authors:  Peixin Dong; Zhujie Xu; Nan Jia; Dajin Li; Youji Feng
Journal:  Mol Cancer       Date:  2009-11-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.